Last reviewed · How we verify
Trovert (somavert)
At a glance
| Generic name | somavert |
|---|---|
| Sponsor | Pfizer |
| Drug class | Growth Hormone Receptor Antagonist |
| Target | Growth hormone receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
- Acromegaly
Common side effects
- Infection
- Pain
- Nausea
- Diarrhea
- Flu syndrome
- Abnormal liver function tests
- Injection site reaction
- Dizziness
- Accidental injury
- Back pain
- Sinusitis
- Peripheral edema
Serious adverse events
- Marked transaminase elevations
- Anaphylactic reactions
- Laryngospasm
- Angioedema
- Systemic hypersensitivity reactions
- Lipohypertrophy at injection sites
- Substantial weight gain
- Chronic hepatitis
Key clinical trials
- Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance (PHASE2)
- Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess (PHASE3)
- Effects of Pasireotide Lar Therapy on Bone Metabolism
- Korean Regulatory Post Marketing Surveillance for Somavert
- PegvisOMant and the Immune SystEm (PROMISE)
- The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
- Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trovert CI brief — competitive landscape report
- Trovert updates RSS · CI watch RSS
- Pfizer portfolio CI